DANISH PHARMACEUTICALS

Bavarian Nordic to buy travel vaccine portfolio for up to $380 mln

The company said it would acquire a typhoid fever vaccine, one against cholera and a Chikungunya virus treatment that is in Phase III trials. There are no approved vaccines against Chikungunya as yet, the company said, adding that analysts peg potential annual income from the vaccine at $500 million.